If your clinic sees patients who have been through the diagnostic gauntlet of unexplained fatigue, cognitive dysfunction, post-exertional malaise, capillary leak, and abnormal TGF-β1 — and who have already been worked up for autoimmune disease, Lyme, dysautonomia, and everything in between — you are almost certainly seeing Chronic Inflammatory Response Syndrome (CIRS) presentations, whether you've labeled them that way or not. CIRS sits at an uncomfortable intersection of mainstream immunology and frontier clinical medicine, and the practitioners who can navigate it competently are increasingly in demand. At the center of that conversation is one neuropeptide: Vasoactive Intestinal Peptide (VIP).
VIP is not a wellness peptide. It is not a 'longevity stack' ingredient. It is the terminal step in the Shoemaker CIRS protocol — the molecule deployed only after a patient has been removed from biotoxin exposure, cleared of MARCoNS colonization, and stabilized across a cascade of inflammatory biomarkers. Used correctly under physician supervision, research-grade VIP is one of the most mechanistically elegant tools in the peptide formulary. Used incorrectly — or sourced from anything less than cGMP-grade material — it can produce significant hemodynamic and immunologic consequences. This article is for the clinicians who want to understand why.
What Is Vasoactive Intestinal Peptide?
VIP is a 28-amino-acid neuropeptide originally isolated from porcine duodenum in 1970, but its 'intestinal' name dramatically undersells its biology. VIP is expressed throughout the central and peripheral nervous systems, the gut, the lungs, the heart, and across virtually every immune cell lineage. It belongs to the secretin/glucagon superfamily and signals primarily through two class B G-protein-coupled receptors: VPAC1 and VPAC2, with secondary activity at PAC1.
The receptor distribution explains the breadth of effect. VPAC1 is expressed constitutively on T lymphocytes, macrophages, and epithelial cells — making it the dominant receptor for VIP's immunomodulatory tone-setting. VPAC2 is upregulated on activated immune cells and predominates in vascular smooth muscle, where it mediates VIP's potent vasodilatory action. Downstream, both receptors couple to Gαs, elevating intracellular cAMP and shifting cells toward an anti-inflammatory transcriptional program: suppression of NF-κB, downregulation of TNF-α, IL-6, and IL-12, and a documented shift from Th1/Th17 toward Th2 and regulatory T-cell phenotypes.
From a synthesis standpoint, VIP is produced via standard solid-phase peptide synthesis (SPPS), typically Fmoc chemistry, and is supplied as a lyophilized acetate salt. It is unstable in plasma — half-life is measured in minutes — which is why the clinical research formulation is intranasal: nasal mucosal absorption bypasses first-pass degradation and, importantly, allows direct access to the olfactory and trigeminal pathways into the CNS.
The Research: VIP, MSH, and the CIRS Biomarker Cascade
The clinical rationale for VIP in CIRS rests on a specific endocrine observation: patients with biotoxin-driven chronic inflammation reliably present with suppressed α-melanocyte stimulating hormone (α-MSH), suppressed VIP, elevated TGF-β1, elevated C4a, and elevated MMP-9. The Shoemaker model proposes that this pattern reflects hypothalamic-pituitary disruption secondary to innate immune activation, with VIP and α-MSH functioning as paired regulatory neuropeptides whose loss perpetuates the inflammatory state.
Recent work by DiTulio and Navarro-Torres (2026) provides important mechanistic support for this paired-neuropeptide model [1]. In their cohort of patients evaluated for CIRS, clearance of multiply antibiotic-resistant coagulase-negative staphylococci (MARCoNS) — a deep-nasal-cavity colonization that is itself an obligatory step before VIP initiation in the Shoemaker protocol — was selectively associated with higher circulating α-MSH. The clinical implication is significant: α-MSH suppression in these patients does not appear to be a fixed endocrinopathy. It is dynamic, and it responds to elimination of the upstream colonization driving local cytokine production. Practitioners who attempt to skip MARCoNS eradication and move directly to VIP are, on this evidence, treating downstream of an unresolved input.
The second pillar of the clinical literature is case-based but mechanistically detailed. Gunn, Gunn, and Mueller (2016) published a case report in the American Journal of Case Reports documenting the resolution of refractory ulcerative colitis and severe chronic fatigue syndrome symptoms in an HLA-DR/DQ genetically susceptible individual with multiple biotoxin exposures [2]. The patient had failed conventional immunosuppression. Following systematic application of the CIRS protocol — exposure removal, cholestyramine binding, MARCoNS eradication, and ultimately intranasal VIP — the patient experienced normalization of inflammatory markers and symptom resolution durable enough to warrant publication. The case is notable not because n=1 establishes efficacy, but because it documents the biomarker trajectory in a genetically susceptible host and demonstrates that VIP's role is sequence-dependent within a larger protocol, not a standalone intervention.
Beyond CIRS specifically, the broader VIP literature supports the immunologic plausibility of these findings. Preclinical models consistently demonstrate VIP-mediated suppression of pro-inflammatory cytokine production, expansion of CD4+CD25+Foxp3+ regulatory T cells, and protection against experimental colitis, arthritis, and septic shock. The molecule also has well-documented pulmonary vasodilatory effects and is being studied in the context of pulmonary arterial hypertension and sarcoidosis. None of this constitutes evidence of efficacy in any specific human disease state outside of carefully controlled research protocols — but it does explain why VIP is the molecule the CIRS literature consistently returns to.
Clinical Considerations: Where VIP Fits in the Protocol
The single most important clinical point about VIP is that it is a finishing peptide, not a starting peptide. The Shoemaker protocol — which represents the most systematized clinical use of VIP in the United States — establishes a sequence of prerequisites that must be satisfied before VIP is introduced. Practitioners deviating from this sequence consistently report either lack of response or, in some cases, paradoxical inflammatory flares.
Prerequisites Before VIP
Before VIP is considered in a research protocol, the following are typically confirmed: removal from ongoing biotoxin exposure (verified by ERMI or HERTSMI-2 environmental testing); normalization of MSH-suppressing colonization, particularly MARCoNS clearance via deep nasal culture [1]; trending of VEGF, C4a, TGF-β1, and MMP-9 toward acceptable ranges; and stabilization of any antigliadin antibodies, ADH/osmolality dysregulation, and androgen disruption. VIP is contraindicated in patients with active biotoxin exposure — administering it in that context is widely understood within the CIRS community to risk significant adverse response.
Dosing and Administration
Research protocols use intranasal VIP, typically at 50 mcg per spray, with dosing escalated cautiously from once daily to four times daily over a period of weeks to months. A 'VIP trial' is typically conducted in-clinic, with pre-dose and 15-minute post-dose blood pressure measurement, because VPAC2-mediated vasodilation can produce clinically meaningful hypotension in susceptible patients. Lipase is also monitored periodically, as VIP-secreting tumors (VIPomas) are associated with pancreatic effects and the research formulation is treated with appropriate caution.
What Practitioners Are Tracking
Within research protocols, the markers tracked over a VIP course include serial VIP levels, TGF-β1, C4a, VEGF, and — increasingly — α-MSH, given the DiTulio findings suggesting it is a dynamic and informative marker of upstream colonization status [1]. Patient-reported outcomes include exercise tolerance, cognitive symptoms, and the Visual Contrast Sensitivity (VCS) screen, which is sensitive to biotoxin-mediated neuroinflammation.
What to Look for in a Source
VIP is one of the peptides where sourcing matters most, for three reasons. First, the molecule is structurally fragile: improper synthesis or storage produces deamidation and oxidation byproducts that can alter receptor binding. Second, the clinical population is, by definition, immunologically hypersensitive — these are patients whose innate immune systems are pattern-recognizing at a level above baseline, and they will react to endotoxin contamination that healthier patients would tolerate silently. Third, intranasal administration bypasses several of the body's protective filters, making purity non-negotiable.
When evaluating a research-grade VIP supplier for physician-supervised protocols, the documentation standard should include: a current Certificate of Analysis from a third-party laboratory specifying HPLC purity (≥98%), mass spectrometry confirmation of molecular weight, residual solvent quantification, and endotoxin testing by LAL assay. Manufacturing should occur in a cGMP-compliant facility, with documented chain of custody from synthesis through final fill. Suppliers who cannot produce lot-specific COAs on request, or who supply 'pooled' COAs that do not match the lot number on the vial, should be disqualified immediately. For a peptide in this clinical context, anything less is not a cost-saving — it is a liability.
Why This Matters for Your Practice
CIRS patients are, structurally, among the most underserved patient populations in American medicine. They have typically seen six to twelve providers before arriving at a clinic that understands the framework. They have spent thousands of dollars on workups that returned 'normal.' They are highly engaged, highly motivated, and — critically for clinic economics — they refer aggressively when they find a practitioner who can articulate what is happening to them.
Building a competent CIRS-aware practice does not require abandoning the rest of your clinical work. It requires three things: the diagnostic literacy to recognize the biomarker pattern (TGF-β1, C4a, MMP-9, VEGF, MSH, VIP, with appropriate HLA-DR/DQ context); the environmental and microbiologic workflow to address exposure and colonization upstream of peptide therapy; and the sourcing infrastructure to deploy research-grade VIP in the small subset of patients for whom it is appropriate. The practitioners who have built this competency are, in our experience, operating with patient waitlists that the conventional functional medicine practice does not see.
The neuropeptide-immune interface that VIP exemplifies is also where the next decade of clinical peptide research is going to be most productive. The DiTulio data on α-MSH dynamism [1] and the Gunn case report on protocol-dependent recovery in HLA-susceptible hosts [2] are signals of a broader shift: away from the idea that chronic inflammation is a fixed endocrinopathy, and toward the idea that it is a modifiable network state with identifiable upstream drivers. VIP is, for now, the most clinically advanced peptide tool in that network. Practitioners who understand it — its mechanism, its prerequisites, its limitations, and its sourcing — are positioning themselves at the front edge of a clinical category that is only going to grow.
VIP is not a peptide you add to a stack. It is a peptide you earn the right to use by doing the rest of the protocol correctly first.
Golden Lotus Labs supplies research-grade VIP and the associated CIRS-protocol peptides exclusively to licensed healthcare providers operating under physician-supervised clinical research protocols. All material is cGMP-manufactured with lot-specific third-party COAs available on request. For sourcing inquiries, clinical questions, or protocol consultation, contact your GLL clinical liaison.